The Complete Guide to Pharmaceutical
Product Registration in Iraq

1. Executive Summary

Most guides to Iraqi registration describe paperwork. This one begins with the change that matters more than any document: as of 30 June 2025, Iraq no longer allows you to sell while you register.

Until that date, a foreign manufacturer could obtain preliminary registration — also referred to as fast-track — which permitted importation and commercial supply for up to two years while the final registration file was being completed. Revenue could begin early; the remaining regulatory work ran alongside the business.

That mechanism was discontinued. The consequence is not a heavier file. It is a fundamentally different cash-flow model: no importation, no supply, and no revenue until final registration is complete.

If your Iraq business case was built before mid-2025, it was built on a revenue timeline that no longer exists. This guide sets out the pathway as it now operates — the requirements, the time ceilings that terminate files, the legalisation chain that stalls more submissions than any technical deficiency, and the decisions that determine whether registration produces a commercial product or an expensive certificate.

2. Why This Matters

Iraq imports the overwhelming majority of its pharmaceutical products, across both the public channel (KIMADIA procurement) and a rapidly growing private sector.

Yet Iraq's registration index tells a striking story: more than 1,800 registered companies and over 12,600 registered products — with a median of one registered product per manufacturer. Fewer than one in five holds more than two.

Companies do not fail to enter Iraq. They enter, and then stop.

Part of that pattern now has a clear explanation. Many manufacturers entered under preliminary registration, began supplying, and treated completion of the final file as a background task. When the mechanism ended, those incomplete files ended with it.

3. The Regulatory Framework

Who registers products. Registration is administered by the Registration Department, Directorate of Technical Affairs, Ministry of Health, Baghdad. Quality control testing is conducted through the national drug control and research centre. KIMADIA — the state company for the marketing of medicines and medical appliances — handles public-sector procurement, and is a separate track from registration itself.

Two channels, one registration. Registration is the gate; channel is a commercial decision made after it: - Public channel — KIMADIA tenders serving government facilities - Private channel — private importers, distributors, pharmacies, private hospitals

The channel decision should precede the dossier, not follow it — it shapes pricing strategy, volume assumptions and partner selection.

A prerequisite most first-time entrants miss. A foreign manufacturer cannot register directly. Registration requires a licensed scientific bureau in Iraq, formally authorised by the manufacturer through legalised authorisation. Every subsequent regulatory action passes through that entity.

⭐ ESHNUNNA Insight

The most consequential decision in Iraqi market entry is made before any dossier exists: the appointment of the scientific bureau, and the scope of what is granted to it.

We regularly see manufacturers grant broad exclusive rights early, then successfully commercialise only part of the portfolio. The remaining products become difficult to reallocate — not for regulatory reasons, but contractual ones. The manufacturer holds a market position it can neither use nor easily exit.

Best practice: define your registration and distribution strategy before signing long-term exclusive agreements. Structure exclusivity around performance, product scope and time — not around the relationship.

4. What Changed on 30 June 2025

4.1 What preliminary registration actually was

Preliminary registration (fast-track) was not merely an abbreviated document set. It was a provisional registration that permitted importation and commercial supply while the final registration file was completed — granted once only per product.

Its practical effect was commercial, not administrative: revenue could begin while regulatory work continued.

4.2 The decision

Regulatory fact. The Ministry of Health, Directorate of Technical Affairs, Registration Department, issued letter no. D.A.F/2/9/5758 dated 7 July 2025, implementing the decisions of the Drug Policy Committee (Session 13 of 2025, convened 24 June 2025), approved by the Technical Deputy Minister's office under letter no. 64026 of 30 June 2025. Decision: discontinuation of the preliminary registration mechanism for foreign pharmaceutical products, across both the public and private sectors. Effective: 30 June 2025. Receipt of preliminary registration files ceased accordingly.

4.3 The transition window — and why it matters now

Files already submitted under preliminary registration before 30 June 2025 were granted a period until January 2026 to complete outstanding deficiencies and requirements. Files not completed within that window were closed.

That window has now closed.

⭐ ESHNUNNA Insight

This is the most commercially significant fact in this guide, and the least widely understood.

Any manufacturer that held an incomplete preliminary file and did not complete it by January 2026 no longer has an open file — and in our experience, many do not yet know. Head offices assume the file is progressing because no one told them otherwise; the local representative may not have escalated the deadline.

If your company submitted a preliminary registration file before mid-2025 and has not received a final registration decision, verify its status immediately. A closed file is not a delay — it is a restart, under the full pathway, with fees paid again.

Best practice: request written confirmation of the current status of every Iraqi file in your portfolio, product by product, with the date of last action. Do it this quarter.

4.4 What replaces it

There is no abbreviated alternative. All foreign products follow the full dossier pathway to final registration, and importation begins only after final registration is granted.

⭐ ESHNUNNA Insight

The correct response is not to abandon expansion — it is to batch it. Company-level documentation, the legalisation chain, and pricing groundwork are largely shared across products. Registering four products together costs substantially less, in both time and fees, than registering them sequentially.

Manufacturers still operating on a one-product-at-a-time rhythm inherited that rhythm from the preliminary-registration era, when early revenue justified it. Under the current pathway, sequential registration is the most expensive way to build an Iraqi portfolio.

5. Time Ceilings — The Deadlines That Terminate Files

Iraqi registration operates under defined time ceilings. These are not service-level targets; exceeding them terminates the file.

• One year for technical review of the file
• Two years from the date of payment of the product fees

A file that exceeds its ceiling is cancelled and its study ended — regardless of how much of the dossier was completed.

Suspension of registration occurs where: specifications are not met on one occasion · incorrect documents are submitted · a product with the same trade name and design already exists · safety warning reports are received regarding the product · the product fails bioequivalence or dissolution studies where applicable.

Cancellation and termination of the file occurs where: specifications are not met on a second occasion · the time ceiling is exceeded · bioequivalence is rejected a second time.

A product will not be registered where it fails specification testing at the national control centre twice, or fails bioequivalence twice.

⭐ ESHNUNNA Insight

The time ceiling is where preventable failures become permanent ones. A deficiency letter that sits unanswered for four months because it was routed to the wrong department at head office does not extend the clock.

Best practice: appoint a single named owner for the Iraqi file with authority to obtain documents directly from manufacturing, quality and regulatory functions. The most common cause of ceiling breaches is not difficulty — it is internal routing.

6. Required Documentation

Company level: manufacturer/site registration · legalised scientific bureau authorisation · registration of every manufacturing site named in the CPP — bulk manufacturer, primary packager, batch releaser, pellets manufacturer and similar — excluding secondary packaging only.

Product level: - Certificate of Pharmaceutical Product (CPP) — original, legalised, naming Iraq as importing country. Where the trade name in the country of origin differs from the name submitted for registration, the CPP must state both names - Completed registration application form, stamped and signed on every page - Pricing certificate — ex-factory, CIF Iraq, CIF Europe, CIF neighbouring countries - Full composition, with the function of each component - Manufacturing method, flow chart, in-process specifications - Finished-product specification, certificate of analysis, analytical method and its validation - Stability studies — long-term and accelerated, three batches - Certificate of Suitability for the active substance, or GMP certificate of the API manufacturer with COA and specification - Certificates of analysis for active and inactive raw materials - Absence declarations — diethylene glycol, porcine derivatives, ethanol, BSE/TSE - Halal certification where gelatin is used - List of countries where registered, with numbers and dates - Full artwork — outer carton, inner label with dimensions and colours, package insert — in Arabic and English - Physical samples, unexpired - Electronic copy of the complete file

Two requirements that fail files quietly: - Storage conditions must be stated on the sample in the prescribed form. Where a 30 °C study cannot be provided, a 25 °C study determines shelf life: a five-year study grants three years; a three-year study grants two years; two years or less grants the period submitted. - Special use warnings — for example sodium metabisulphite, which affects asthmatic patients — must appear on the outer carton in clear print, preferably red, in addition to the package insert.

⭐ ESHNUNNA Insight — the requirement no one anticipates

Documents and clarification letters must bear live company stamps — not scanned, photocopied or digitally reproduced impressions.

This single requirement causes more avoidable rejections than any technical deficiency in our experience. A company assembles a complete, accurate file, transmits it electronically to the scientific bureau, and the entire submission is returned. The content was never in question.

Best practice: confirm at the outset that every document leaving your quality department carries a wet stamp, and that originals — not copies — are physically couriered.

⭐ ESHNUNNA Insight — CPP validity is a scheduling problem

Where a CPP does not state a validity period, a defined default applies — and the certificate must still carry sufficient remaining validity at the point fees are paid, not merely at submission.

Companies routinely submit a CPP that is valid on the day of filing and expired by the time the file reaches the fee stage. The certificate must then be re-issued and re-legalised: three to four months lost to a document that was correct when written.

Best practice: map every certificate's expiry against projected submission and fee dates before you begin. Treat document validity as a project timeline input.

7. Legalisation — The Chain That Stops Files

Original documents require sequential authentication:

1. The competent authority in the country of origin
2. The Ministry of Foreign Affairs of the country of origin
3. The Iraqi Embassy in the country of origin — or, where none exists, the Iraqi Embassy in a neighbouring country
4. The Iraqi Ministry of Foreign Affairs in Baghdad

Documents issued in languages other than English require certified translation authenticated in the country of origin.

⭐ ESHNUNNA Insight

More Iraqi timelines are lost to legalisation than to technical review, for a structural reason: legalisation is delegated to logistics or administrative teams who do not know the chain is sequential, and that a break at step 3 invalidates steps 1 and 2.

Best practice: assign legalisation to a named owner with the sequence written out, begin it in parallel with dossier drafting rather than after it, and build a realistic buffer. It is the highest-return scheduling decision in the entire process.

8. Why Files Fail — Beyond Documentation

Registration is a regulatory process with commercial consequences. Five failure patterns recur, and only one of them is technical. (Each is examined in depth in our companion guide, The Five Most Common Mistakes International Pharmaceutical Companies Make When Entering Iraq.)

1. Pricing assessed after registration, not before. The most expensive mistake in this market. A dossier is completed, submitted and approved — and the resulting official price does not support a viable business model. The registration is technically successful and commercially worthless.

⭐ ESHNUNNA Insight — pricing can be assessed before you register

Iraq operates a preliminary pricing assessment mechanism. For a modest official fee — currently 100,000 IQD under standard processing, or 200,000 IQD for expedited handling — a manufacturer can obtain a pricing indication before committing to the cost of full registration.

Set that against the alternative: a complete dossier, legalisation, fees and a year of internal effort, ending in an approved price that does not support the business. The assessment costs a fraction of one percent of what it protects.

What determines your price. Iraqi pricing is not set product by product in isolation. It is referenced: the originator (brand) price establishes the anchor, and generic pricing is then set as a defined proportion of that anchor — with the proportion determined by the country of origin of the manufacturing site.

The practical consequence is decisive: two manufacturers producing an identical molecule to identical standards will receive materially different Iraqi prices, based on where they manufacture. The spread between origin tiers is wide enough to determine whether a product is commercially viable at all — before a single document is prepared.

This is why pricing must be the first analysis, not the last. A manufacturer in a lower-referenced tier may still succeed in Iraq — but on a volume model, not a margin model, and that decision changes portfolio selection, channel strategy and partner requirements entirely.

Best practice: establish your expected price band and resulting margin before dossier preparation begins. If the number does not work, the correct decision is not to register — and taken first, that decision costs almost nothing.

2. Documentation that does not meet Iraqi requirements. Missing bioequivalence where required; stability data prepared for temperate markets that does not satisfy Iraq's climatic conditions; incomplete regulatory documentation. Each surfaces after substantial investment. Recommendation: conduct a comprehensive regulatory gap analysis before any submission.

3. Exclusive rights granted too early. See Section 3.

4. A partner selected without regulatory capability. Manufacturers have spent years with a local representative without a single successful registration — not through bad faith, but because promotion and regulatory affairs are different competencies. Recommendation: a scientific bureau should understand regulatory affairs, pricing strategy, market access and commercialisation — not promotion alone.

5. Weak distribution strategy. Registration does not guarantee commercial success. Over-reliance on sub-distributors without coordination across governorates produces inconsistent coverage, internal competition and reputational damage. Recommendation: evaluate nationwide distribution capability, field force, reporting systems and performance management before entering.

9. Registration Maintenance

Registration is granted for five years from the date of registration or previous re-registration. Re-registration procedures and fee payment must begin six months before expiry — otherwise the registration is treated as suspended.

Product shelf life is capped at three years owing to storage conditions in-country, except solid oral dosage forms, which may be granted up to five years according to the stability study submitted, not exceeding the reference product's shelf life.

Changes to a registered product are not accepted where fewer than six months remain on the registration — they must instead be submitted with the re-registration file.

⭐ ESHNUNNA Insight

The six-month rule catches companies twice: once on renewal, and once on variations. A packaging or artwork change approved internally in month 55 cannot be filed — it waits for re-registration.

Best practice: maintain a rolling 18-month calendar of every Iraqi registration expiry, and treat month 48 as the internal trigger for renewal planning.

10. CEO Checklist

Before committing to Iraqi market entry:

☐ Have we verified the current status of every existing Iraqi file, product by product? ☐ Have we assessed pricing feasibility before dossier preparation — including a preliminary pricing assessment? ☐ Do we know which origin-referenced pricing tier applies to our manufacturing site? ☐ Does our documentation meet Iraqi requirements — bioequivalence, stability, climatic conditions? ☐ Have we identified every manufacturing site that must be registered? ☐ Do all documents carry live stamps, and are originals being couriered? ☐ Have we mapped certificate validity against submission and fee dates? ☐ Is legalisation assigned to a named owner and started in parallel? ☐ Have we chosen our channel — public, private, or both — before the dossier? ☐ Is our scientific bureau selected on regulatory capability, not relationship? ☐ Have we defined portfolio strategy before granting exclusivity? ☐ Are we registering products in batches rather than sequentially?

11. How ESHNUNNA Supports Market Entry

ESHNUNNA Scientific Bureau operates as a licensed scientific bureau in Baghdad, working with international manufacturers across the full entry pathway: regulatory strategy and registration, import authorisation, distribution and market access, and pharmacovigilance representation.

Our work begins before the dossier. We conduct a structured readiness assessment covering documentation status per product, pricing exposure, channel strategy and legalisation planning — identifying the gaps that would otherwise surface after the investment is made.

We operate on compliant pathways only. No shortcuts, no grey areas.

12. Frequently Asked Questions

Is fast-track or preliminary registration still available? No. The preliminary (fast-track) registration mechanism for foreign pharmaceutical products was discontinued effective 30 June 2025, for both public and private sectors, per Registration Department letter no. D.A.F/2/9/5758 of 7 July 2025.

Can we still import while completing registration? No. That was the principal commercial function of preliminary registration. Importation now follows final registration.

We submitted a preliminary file before mid-2025. What happened to it? Files submitted before 30 June 2025 were given until January 2026 to complete outstanding requirements; files not completed were closed. That window has passed. Verify your file's status in writing.

Can we register directly, without a local partner? No. Registration requires a licensed scientific bureau in Iraq, formally authorised by the manufacturer.

How long does registration take? It varies by product type, dossier completeness and legalisation status. What is fixed are the ceilings: one year for technical review, and two years from payment of product fees — after which the file is terminated.

Does approval in the EU or US shorten the process? It improves documentation quality; it does not create an abbreviated pathway. Since June 2025 no such pathway exists.

How long is registration valid? Five years, with renewal procedures and fees starting six months before expiry.

Can we find out the likely price before registering? Yes. A preliminary pricing assessment is available for an official fee (currently 100,000 IQD standard, 200,000 IQD expedited). Given that Iraqi pricing is referenced to the originator product and adjusted by country of manufacturing origin, this assessment is the single most cost-effective risk control available before entry.

What is KIMADIA, and do we need it? KIMADIA is the state company handling public-sector procurement — a separate track from registration. Registered products may be supplied through the public channel via KIMADIA tenders, the private channel, or both.

13. Disclaimer

This guide is provided for general informational purposes for international pharmaceutical companies evaluating the Iraqi market. It does not constitute legal, regulatory or commercial advice, and does not replace official regulations or decisions issued by the Iraqi Ministry of Health.

Iraqi pharmaceutical regulations are subject to change, and requirements may vary by product category and individual case. Companies should confirm current requirements with the competent authorities or through a licensed scientific bureau before taking any action.

Regulatory basis: Ministry of Health registration regulations, verified current · Registration Department letter no. D.A.F/2/9/5758 of 7 July 2025.